Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
Neurogene Inc. shares barely moved in premarket trading on Nasdaq Thursday. Investors looked past new disclosures and kept their eyes on the upcoming clinical milestone for NGN-401, the lead gene therapy for Rett syndrome. The stock finished Wednesday at $26.95, gaining 7 cents, or 0.3%. It traded in a range from $26.50 to $28.08. Broader markets rallied too, with the Nasdaq Composite adding 1.5% and the Russell 2000 up 2.6% on Wednesday.